TRIM33 and cancer: These events could reduce the expression of the mutant isoforms of TIF1γ—and thus reduce the immunogenicity of the malignant cell—and upregulate the Wnt/β-catenin TGF-β/Smad signaling pathways that promote cancer cell survival.